MAP2K7 and non-small cell lung carcinoma: However, BI 1701963 alone or in combination with irinotecan in patients with advanced bowel cancer with KRAS mutations (NCT04627142) and BI 1701963 alone or in combination with MEK inhibitor BI 3011441 in patients with KRAS mutant non-small cell lung cancer and colorectal cancer (NCT04835714) were terminated recently due to the unexpected toxicity.